Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment
Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2016
Συγγραφείς:
Weisel, Katja Dimopoulos, Meletios A van de Donk, Niels WCJ Ramasamy, Karthik Gamberi, Barbara Streetly, Matthew Offidani, Massimo Bridoux, Frank de la Rubia, Javier Kueenburg, Elisabeth others
